BIO-B : Summary for Bio-Rad Laboratories, Inc. Clas - Yahoo Finance

U.S. Markets closed

Bio-Rad Laboratories, Inc. (BIO-B)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
187.45-0.55 (-0.30%)
At close: 4:03PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close188.00
Bid0.00 x
Ask0.00 x
Day's Range182.65 - 187.45
52 Week Range124.50 - 188.00
Avg. Volume62
Market Cap5.65B
PE Ratio (TTM)56.39
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Marketwired5 hours ago

    Bio-Rad to Report Fourth-Quarter and Full-Year 2016 Financial Results Thursday, February 23, 2017

    Bio-Rad Laboratories, Inc. , a global provider of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2016 on Thursday, February 23, ...

  • PR Newswire6 hours ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bio-Rad Laboratories, Inc. - BIO

    NEW YORK, Jan. 18, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company") (NYSE: BIO).   Such investors are advised to contact Robert S. Willoughby at or 888-476-6529, ext. 9980. On May 27, 2015, Bio-Rad's former General Counsel Sanford Wadler filed a lawsuit alleging that he was fired in 2013 after raising concerns to the Company's audit committee about bribery practices in China and for refusing to turn a blind eye to corruption.  On this news, the Company's stock fell $1.63, or $1.13%, to close at $142.36 on May 28, 2015.

  • The Wall Street Journalyesterday

    [$$] Bio-Rad to Acquire Former IPO Aspirant RainDance

    Bio-Rad Laboratories Inc. has agreed to acquire RainDance Technologies Inc., a venture-backed developer of genomics tools that once aspired to a public listing.